AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01226563 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
Study NCT00970125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: outline of the goals of care
Study NCT01134601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01134601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01134601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Study NCT02986061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter
Study NCT03244462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Single oral dose (IR \[immediate release\] tablets)
Study NCT03244462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: I.v. infusion of \[13C6\]-labeled BAY1834845
Study NCT03244462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Single dose of commercially available MTX
Study NCT01262443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
Study NCT04398446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemp-based CBD
Description: 3x Daily dosing for 12 weeks
Study NCT04398446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 3x Daily dosing for 12 weeks
Study NCT03154281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Description: Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
Study NCT03154281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
Study NCT02884414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutaneous stimulation
Description: A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
Study NCT00529919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
Study NCT00529919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
Study NCT01729117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal Replacement
Description: 5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
Study NCT01729117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care only
Study NCT00602680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180711C
Description: duration of treatment: 4 weeks
Study NCT00602680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: duration of treatment: 4 weeks
Study NCT00602680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: duration of treatment: 4 weeks
Study NCT02873130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepractice Global Voice Prevention Model
Study NCT02873130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person Global Voice Prevention Model
Study NCT02873130 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Telepractice, Vocal Hygiene and Vocal Education
Study NCT03353259 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid and Tocilizumab
Description: The first intervention is Tranexamic acid, The second intervention is Tocilizumab
Study NCT02815787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
Study NCT02815787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
Study NCT01678014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation(DBS)
Description: Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
Study NCT02880774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandibular nonspecific mobilization
Description: The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
Study NCT02880774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound detuned,
Description: Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
Study NCT02256982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02256982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01678014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulotomy
Study NCT02256982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical Resection and Lymphadenectomy
Study NCT02256982 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy
Study NCT04164043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Program
Description: 12-week community-based recreation therapy
Study NCT03761030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA
Description: We will be using generic sinemet 25/100 tablets in this study.
Study NCT03761030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 25/100 placebo tablets
Study NCT01844661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELYVIR
Study NCT03381300 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue cryopreservation
Description: Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
Study NCT04313179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Mozart lullaby music
Study NCT04313179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 0.5 ml of 24% Sucrose
Study NCT04313179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 0.5 ml of 24% Sucrose
Study NCT03103373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional monitor
Description: Patients underwent non-cardiac surgery will be monitoring by regular monitors
Study NCT03103373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Patients will be monitoring by regular monitors plus echocardiography
Study NCT03224611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: light wand
Description: The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light.
Study NCT05146544 — intervention group
Intervention type: OTHER
Intervention: Heart Rate Recording
Description: During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
Study NCT03764878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: Participants will undergo a functional MRI using multiple imaging modalities.
Study NCT03486587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Cereus tablets
Description: Bacillus Cereus tablets was taken two tablets three times a day.
Study NCT03919786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical local anesthesia of pulmonary vein combined with vagus nerve block
Description: Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex.
Study NCT03919786 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: topical local anesthesia of pulmonary vein combined with vagus nerve block
Description: Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex.
Study NCT02648971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Portal Knee Arthroscopy
Description: Patients in Group 1 will undergo knee arthroscopy using a single portal.
Study NCT02648971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Portal Knee Arthroscopy
Description: Patients in Group 2 will undergo knee arthroscopy using two portals.
Study NCT03107819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma and urine metabolomics
Description: Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
Study NCT00509002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg by mouth once a day, every day, at about same time in morning.
Study NCT00146250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
Study NCT03450655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program
Description: An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
Study NCT00618696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD45 monoclonal antibody AHN-12
Description: 150 mg/m\^2 cold antibody at Day 0
Study NCT00618696 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
Description: Dose per scheduled level; 2.5-12.5 mCi/m\^2
Study NCT04637464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early termination of empirical antibiotics
Description: Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
Study NCT01641926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron™
Description: PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
Study NCT01641926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS™
Description: PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
Study NCT04367038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Acupressure, Cold Acupressure , Conventional Acupressure
Description: Acupressure is non-invasive, safe and effective.
Study NCT02673710 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 30
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 40
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 50
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administrated subcutaneously (s.c., under the skin) as comparator.
Study NCT01865305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administrated subcutaneously (s.c., under the skin).
Study NCT01664520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments
Study NCT02294630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant
Description: Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
Study NCT04040881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote monitoring using smartphone accelerometer
Description: Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions.
Study NCT05103163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
Study NCT04131478 — intervention group
Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Pharmacogenetic testing for TNF alfa
Study NCT01822938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: incentive program for physical activity
Study NCT02923102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aloysia citriodora extract
Description: 2 capsules with 200mg - daily dosage 400mg
Study NCT02923102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 2 capsules with 200mg - daily dosage 400mg
Study NCT00310895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium (GRN163L)
Description: Dose increase by 25% if tolerated infused over 2 hours
Study NCT00992537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Study NCT00992537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Study NCT00992537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Study NCT03645135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal elicitation
Description: Patients will be asked to list 2 goals for their visit
Study NCT01746420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB Injection
Description: Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Study NCT01746420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sodium acetate buffer (0 mg rhPDGF-BB)
Study NCT02117908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESMED AUTOSET S9
Description: Continuous positive pressure during surgery
Study NCT02117908 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RESMED AUTOSET S9
Description: Continuous positive pressure during surgery
Study NCT03554863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Oxygen
Description: Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
Study NCT03554863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial Mask
Description: Preoxygenation with facial mask
Study NCT02158468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined intrahospital pre- and postconditioning
Description: After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
Study NCT02158468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postconditioning
Description: After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)